OSI (OSIS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

OSI Systems (OSIS) reported Q4 2025 revenue of $504.99 million and EPS of $3.24, exceeding Zacks Consensus Estimates by 2.34% and 1.57% respectively, primarily driven by robust performance in its Security and Optoelectronics divisions. However, the Healthcare division's revenue declined 15.2% year-over-year and its operating income significantly missed analyst projections, contrasting with the overall top-line beat. Despite these mixed divisional results and recent underperformance against the S&P 500, OSIS currently holds a Zacks Rank #2 (Buy), indicating potential for near-term outperformance.

Analysis

OSI Systems reported a mixed financial performance for its fourth quarter ending June 2025, beating top and bottom-line consensus estimates while revealing significant underlying weakness in a key division. Overall revenue grew 5% year-over-year to $504.99 million, surpassing the Zacks Consensus Estimate by 2.34%, and EPS of $3.24 represented a 1.57% beat. This outperformance was driven by the company's two largest segments: the Security division, which saw revenues grow 7.1% YoY to $366.97 million, and the Optoelectronics and Manufacturing division, with revenues up 10.4% YoY to $112.67 million, both exceeding analyst expectations. However, this strength was significantly offset by the Healthcare division, where revenue declined 15.2% YoY to $42.68 million, missing estimates of $50.9 million. More critically, the Healthcare division's non-GAAP operating income collapsed to just $0.37 million, falling dramatically short of the $4.31 million analyst estimate, indicating severe margin pressure or operational challenges. Despite the headline earnings beat, the stock has underperformed the S&P 500 over the past month with a -1.4% return, reflecting investor concern over this divisional weakness, which contrasts with its current Zacks Rank #2 (Buy) status.

Key Decisions for Investors

• Investors should look beyond the headline revenue and EPS beat to the significant divergence in segmental performance, as the outperformance is entirely dependent on the Security and Optoelectronics divisions.
• The severe underperformance of the Healthcare division, with a 15.2% revenue decline and a near-total collapse in operating income, represents a material risk and should be the primary focus of due diligence in subsequent quarters.
• Given the stock's recent underperformance despite a 'Buy' rating from Zacks, investors should weigh the sustained growth in the Security segment against the substantial drag from the Healthcare unit before initiating or adding to positions.